MRI Assessment of Impaired Glucose Metabolism in Alzheimer's Disease

Completed

• Conditions: Alzheimer Disease
• Interventions: Diagnostic Test: Deuterium metabolic imaging

• Registration Number: NCT05402566
• Lead Sponsor: University of Aarhus

Brief Summary

Diseases of dementia are chronic, untreatable, and cause a massive burden of morbidity. In this proposal, we seek to tackle the problem of better, earlier, and more efficient diagnosis using deuterium metabolic imaging (DMI). The study is divided in two sub-studies: 1) optimization and simplification of DMI protocols, and 2) a cross-sectional study of DMI in Alzheimer's patients and healthy controls.

Detailed Description

Not available

Study Timeline

• Status Verified: 2022-05
• Study First Submitted: 2022-05-25
• Study First Submitted QC: 2022-05-30
• Study First Posted: 2022-06-02
• Study Start: 2022-12-22
• Primary Completion: 2023-10-27
• Study Completion: 2023-10-27
• Last Update Submitted: 2023-11-30
• Last Update Posted: 2023-12-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 21

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Healhy volunteers	Deuterium metabolic imaging	Repeated MRI and DMI for simplification of protocols. Repeated within 6 +/- 2 weeks.
Healthy controls	Deuterium metabolic imaging	MRI and DMI for comparison with AD patients.
Alzheimer's disease patients	Deuterium metabolic imaging	MRI and DMI to assess cerebral glucose metabolism. Single examination. Compared with PET.

Primary Outcome Measures

Name	Time	Method
Deuterium Metabolic Imaging	Up to 150 mins after 2H-glucose ingestion	Lactate/glx ratio in the posterior cingulum (sub-study 2).

Secondary Outcome Measures

Name	Time	Method
Deuterium Metabolic Imaging	Up to 150 mins after 2H-glucose ingestion	Simpler DMI quantifications, including reference to external phantoms and internal reference, in the same regions defined in primary outcomes.
FDG-PET from the records (sub study 2)	At time of Deuterium Metabolic Imaging	Brain glucose uptake
Blood samples	Up to 150 mins after 2H-glucose ingestion	2H-enrichment
Cognitive tests from the records (sub study 2)	At time of Deuterium Metabolic Imaging	Addenbrooke's Cognitive Examination (0-100, 100 is best)
Cerebrospinal fluid biochemistry from the records (sub study 2)	At time of Deuterium Metabolic Imaging	Amyloid

Trial Locations

Locations (1)

Aarhus University; 🇩🇰 Aarhus, Denmark